Transcarent, Inc. announced that it has received $126 million in a round of funding co-led by returning investors, 7wire Ventures and General Catalyst Group Management, LLC on May 2, 2024. The transaction included participation from new investors, Geodesic Capital, Memorial Hermann Healthcare System, Inc., and returning investors, Threshold Ventures Management Company, LLC, Kinnevik AB , Ally Bridge Group, Human Capital Investment Management LLC, Merck Global Health Innovation Fund, LLC, Alta Partners LP, Leaps by Bayer. The transaction was raised at a post money valuation of $2,200 million.

The company has raised a total of around $450 million in funding till date.